한글목차

DZUVEO로 알려진 DSUVIA는 오피오이드 작용제 인 스펜타닐을 함유하고 있으며, 오피오이드 진통제가 필요할 정도로 심각하고 대체 치료가 불충분 한 급성 통증 관리로 인해 병원, 수술센터 및 응급 부등의 인정 의료 감시하의 헬스케어 환경에 있어서의 성인에게의 사용을 적응으로 하고 있습니다.

2021년 1월, AcelRx는 클리블랜드 대학 병원 의료 센터와의 공동 연구로서 특수 회복 강화 프로토콜에 따라 심폐 우회를 사용하는 심장 수술을받는 환자의 긍정적인 코호트에서 본 약의 수술 후 사용을 평가하기 위해 의사 주도 시험을 발표했습니다. 2020년 8월, 정형외과 수술 후 수술 후 회복에 대한 DSUVIA의 효과를 평가하기 위해 Cleveland Clinic과의 의사 주도 연구가 시작되었습니다. 이 이중 맹검 시험은 무릎 관절경을 앓고 있는 환자를 대상으로 DSUVIA와 펜타닐의 정맥내 투여를 비교합니다.

향후 몇 년동안 세계의 광범위한 조사와 의료비 증가로 수술 후 통증 시장 시나리오가 변할 것입니다. 각 회사는 병태를 치료/개선하기 위한 새로운 접근법에 중점을 둔 치료법을 개발하고, 과제를 평가하고, DSUVIA의 이점에 영향을 줄 수 있는 기회를 모색하고 있습니다. 다른 수술 후 통증 치료제도 DSUVIA와 엄격한 시장 경쟁을 벌일 것으로 예상되며, 가까운 미래에 후발 신흥 치료제가 상시되면 시장에 큰 영향을 미칠 것으로 보입니다.

이 보고서는 주요 7개국의 DSUVIA 시장을 조사했으며, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술 후 통증의 DSUVIA 개요

• 제품 상세
• 임상 개발
• 규제 마일스톤
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 DSUVIA 시장 평가

• 수술 후 통증에서 DSUVIA 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"DSUVIA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about DSUVIA for Postoperative pain in the seven major markets. A detailed picture of the DSUVIA for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DSUVIA for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DSUVIA market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

DSUVIA, known as DZUVEO, contains sufentanil, an opioid agonist, and is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

In January 2021, AcelRx announced an investigator-initiated study with University Hospitals Cleveland Medical Center to evaluate the postoperative use of the drug in a prospective cohort of patients undergoing cardiac surgery with cardiopulmonary bypass following a specialized enhanced recovery protocol. In August 2020, an investigator-initiated study with Cleveland Clinic was initiated to assess the effects of DSUVIA on postoperative recovery from orthopedic surgery. This double-blind study compares DSUVIA to IV fentanyl for patients undergoing knee arthroscopy.

Dosage and administration

The recommended dosage of DSUVIA is 30 mcg sublingually as needed, with a minimum of 1 h between doses; do not exceed 12 tablets in 24 h. The maximum cumulative dose is 360 mcg or 12 tablets (12 tablets X 30 mcg/dose).

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DSUVIA description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on DSUVIA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DSUVIA research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around DSUVIA.
• The report contains forecasted sales of DSUVIA for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for DSUVIA in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DSUVIA Analytical Perspective by DelveInsight

• In-depth DSUVIA Market Assessment

This report provides a detailed market assessment of DSUVIA for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• DSUVIA Clinical Assessment

The report provides the clinical trials information of DSUVIA for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DSUVIA dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to DSUVIA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DSUVIA in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of DSUVIA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DSUVIA in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of DSUVIA?
• What is the clinical trial status of the study related to DSUVIA in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DSUVIA development?
• What are the key designations that have been granted to DSUVIA for Postoperative pain?
• What is the forecasted market scenario of DSUVIA for Postoperative pain?
• What are the forecasted sales of DSUVIA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to DSUVIA for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. DSUVIA Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DSUVIA Market Assessment

• 5.1. Market Outlook of DSUVIA in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DSUVIA in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DSUVIA in the United States for Postoperative pain
  • 5.3.2. Market Size of DSUVIA in Germany for Postoperative pain
  • 5.3.3. Market Size of DSUVIA in France for Postoperative pain
  • 5.3.4. Market Size of DSUVIA in Italy for Postoperative pain
  • 5.3.5. Market Size of DSUVIA in Spain for Postoperative pain
  • 5.3.6. Market Size of DSUVIA in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of DSUVIA in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options